News

UK's MHRA suspends Valneva's chikungunya vaccine for elderly
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...
Medscape1h
UK Valproate Restrictions in Men Justified? New Data
A new analysis shows no clear link between paternal valproate use and harm in offspring, raising questions about the EMA ...
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
Devdiscourse9h
Potential Vision Risks Associated with Novo's Weight-Loss Drugs
The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Medscape2h
Evidence Shifts Perspective on Multiple Sclerosis Drug Use During Pregnancy
A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
India Today3d
European drugs regulator flags rare eye risk with Ozempic use
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Consilium5d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...